BioNTech Lifts 2026 Revenue Guidance Midpoint as Roche Takes Over Partner Program R&D Costs
Published on 11/20/2026 at 19:10 | Editorial boerse-global.deBioNTech's stock has been caught in a market-wide downdraft rather than any company-specific storm. More than 90% of S&P 500 constituents fell yesterday, a broad retreat that Associated Press reports was driven by worries over AI stocks, and BioNTech slipped 2.26% alongside it. The decline continued today, with the shares off 1.5% at EUR 73.05.
JPMorgan Keeps Neutral Rating, Nudges Target Higher
Against that soft tape, JPMorgan left its "Neutral" rating on BioNTech unchanged yesterday. Analyst Jessica Fye did raise her price target to $93 from $92.
Roche and Genentech to Carry Future R&D Costs
On the collaboration front, BioNTech has exercised an option in its partnership with Roche and Genentech. From January 1, 2027, the two partners are in principle to bear the future research and development costs for the program concerned. The ongoing adjuvant pancreatic cancer study is to proceed as planned.
Should investors sell immediately? Or is it worth buying BioNTech?
$205 Million for an FDA Fast Lane
BioNTech also struck a deal with Scholar Rock last week to buy a voucher for accelerated review by the US Food and Drug Administration, paying $205 million in cash. The company intends to use it on a future marketing application for one of its late-stage cancer drug candidates. The transaction is subject to customary conditions, including clearance under US antitrust rules.
Guidance Midpoint Raised, Cost Outlook Unchanged
Earlier in November, BioNTech lifted the midpoint of its full-year 2026 revenue guidance. Its forecasts for adjusted research and development costs and for adjusted selling and administrative expenses were left as they were.
For the third quarter of 2026, BioNTech posted revenue of EUR 1.29 billion and an IFRS net profit of EUR 184.5 million. Revenue from the start of the year through the end of the reporting quarter totaled EUR 1.51 billion, a period for which the company reported an IFRS net loss of EUR 1.17 billion.
Ad
BioNTech Stock: New Analysis - 20 November
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
